Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants
Current Opinion in Biotechnology · 2024-12 · 90 · 103223
DOI: 10.1016/j.copbio.2024.103223 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Opinion in Biotechnology, 2024-12. Verfasst von Anna Mei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland; Life Science Zurich Graduate School, ETH Zürich, University of…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cells are a powerful treatment against hematologic cancers. The functional phenotype of a CAR-T cell is influenced by the domains that comprise the synthetic receptor. Typically, the potency of therapeutic CAR-T cell candidates is assessed by preclinical functional assays and mouse models (i.e. human tumor xenografts). However, to date, only a few sets of domains (e.g. CD8, CD28, 41BB) have been extensively tested in preclinical assays and human clinical studies. To characterize the efficiency of a CAR, different assays have been utilized to analyze T cell phenotypes, such as expansion, cytotoxicity, secretome, and persistence. However, each of these previous studies evaluated the importance of an assay differently, resulting in a wide range of functionally diverse CARs. In this review, we highlight recent (high-throughput) methods to analyze CAR domains and demonstrate their impact on inducing T cell phenotypes and activity. We also describe advances in computational methods and their potential for identifying CAR variants with enhanced properties. Finally, we reflect on the need for a standardized scoring system to support the clinical development of next-generation CARs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland; Life Science Zurich Graduate School, ETH Zürich, University of Zurich, 8057 Zürich, Switzerland.
- Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland.
- Department of Biosystems Science and Engineering, ETH Zürich, 4056 Basel, Switzerland. Electronic address: sai.reddy@ethz.ch.
Zitieren
APA
Mei, A., Letscher, K. P., & Reddy, S. (2024). Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants. Current Opinion in Biotechnology, 90, 103223. https://doi.org/10.1016/j.copbio.2024.103223
Vancouver
Mei A, Letscher KP, Reddy S. Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants. Current Opinion in Biotechnology. 2024;90:103223. doi:10.1016/j.copbio.2024.103223
BibTeX
@article{Mei2024,
author = {Mei, Anna and Letscher, Kevin P and Reddy, Sai},
title = {Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants},
journal = {Current Opinion in Biotechnology},
year = {2024},
volume = {90},
pages = {103223},
doi = {10.1016/j.copbio.2024.103223}
}
EUVIMED